The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With ANCA‐Associated Vasculitis
- 5 October 2023
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (12) , 2216-2227
Abstract
Objective: This study examined the relationship between age at diagnosis and disease characteristics and damage in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).Methods: Analysis of a prospective longitudinal cohort of patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA) in the Vasculitis Clinical Research Consortium (2013–2021). Disease cohorts were divided by age at diagnosis (years): children (65). Data included demographics, ANCA type, clinical characteristics, Vasculitis Damage Index (VDI) scores, ANCA Vasculitis Index of Damage (AVID) scores, and novel disease‐specific and non‐disease‐specific damage scores built from VDI and AVID items.Results: Analysis included data from 1020 patients with GPA/MPA and 357 with EGPA. Female predominance in GPA/MPA decreased with age at diagnosis. AAV in childhood was more often GPA and proteinase 3‐ANCA positive. Children with GPA/MPA experienced more subglottic stenosis and alveolar hemorrhage; children and young adults with EGPA experienced more alveolar hemorrhage, need for intubation, and gastrointestinal involvement. Older adults (GPA/MPA) had more neurologic manifestations. After adjusting for disease duration, medications, tobacco, and ANCA, all damage scores increased with age at diagnosis for GPA/MPA (P < 0.001) except the disease‐specific damage score, which did not differ (P = 0.44). For EGPA, VDI scores increased with age at diagnosis (P < 0.009), whereas all other scores were not significantly different.Conclusion: Age at diagnosis is associated with clinical characteristics in AAV. Although VDI and AVID scores increase with age at diagnosis, this is driven by non‐disease‐specific damage items. imageKeywords
Funding Information
- GlaxoSmithKline
- National Center for Advancing Translational Sciences
- National Center for Research Resources (U54‐RR‐019497)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54‐AR‐057319)
- Vasculitis Foundation
This publication has 16 references indexed in Scilit:
- Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician surveyPediatric Rheumatology, 2017
- Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the USArthritis Care & Research, 2016
- Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort StudyArthritis & Rheumatology, 2016
- Differences in disease phenotype and severity in SLE across age groupsLupus, 2016
- Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitidesClinical and Experimental Nephrology, 2013
- The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated VasculitisThe Journal of Rheumatology, 2011
- Classification, presentation, and initial treatment of Wegener's granulomatosis in childhoodArthritis & Rheumatism, 2009
- The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI)Scandinavian Journal of Rheumatology, 2009
- Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitidesArthritis & Rheumatism, 1997
- Wegener granulomatosis in children and adolescents: Clinical presentation and outcomeThe Journal of Pediatrics, 1993